Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.70 |
| ▸ | FPR2 | P25090 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | HRH1 | P35367 | 6/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.51 |
| ▸ | DRD1 | P21728 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 4/20 | 0.51 |
| ▸ | HTR2B | P41595 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673722 | 0.99 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20412134 | 0.99 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20425971 | 0.98 | KDM1A (0.70) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20425968 | 0.97 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20412075 | 0.94 | KDM1A (0.70) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20412079 | 0.93 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL31673733 | 0.93 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20412076 | 0.92 | KDM1A (0.70) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL31673781 | 0.92 | KDM1A (0.70) | KDM1AFPR2DRD3DRD2HRH1 | |
| SCHEMBL20412098 | 0.91 | KDM1A (0.68) | KDM1AFPR2DRD3DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | claimed |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-19 | — | — | US | claimed |
| EP-4260861-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | Seoul National University R & DB Foundation (KR) | 2023-10-18 | — | — | EP | claimed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | claimed |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | disclosed |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-19 | — | — | US | disclosed |
| EP-4260861-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | Seoul National University R & DB Foundation (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | disclosed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | disclosed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP50, NUP188 | KDM1A 2069/4885FPR2 4687/4885DRD3 4881/4885 |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | CALM1, CAMK4, CAMK1 | KDM1A 3642/4885FPR2 3304/4885DRD3 3575/4885 |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP188, NUP50 | KDM1A 1562/4885FPR2 4728/4885DRD3 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.